Observational studyBMC women's health2026
Tracking androgens in female elite athletes: menstrual cycle and hormonal contraceptive effects.
Observational study in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnderstanding variations in the androgen profile is crucial for interpreting hormone data and developing cycle-based training strategies tailored to individual athlete needs. Therefore, this study investigates the androgen concentrations of elite female track and field athletes across various hormonal conditions, including natural eumenorrheic cycles, cycles under hormonal contraception, and cycles with menstrual disturbances.
methodsUsing a prospective, longitudinal observational cohort design, 22 athletes (15 naturally cycling, 7 using hormonal contraception) were monitored for up to three consecutive cycles. The study utilised daily or near-daily urine sampling to analyse urinary steroid hormones (including testosterone and its metabolites) via gas chromatography-coupled mass spectrometry (GC-MS/MS).
resultsResults demonstrated that in athletes with ovulatory menstrual cycles, urinary androgen concentrations, particularly testosterone, varied significantly by phase, peaking around the late follicular phase (lateFP: 7.35 ± 6.25 ng/mL). In contrast, athletes using combined oral contraceptives exhibited significantly suppressed androgen concentrations throughout the cycle compared to the natural cycle group, with mean urinary testosterone levels being notably lower (2.55 ± 2.91 ng/mL vs. 5.45 ± 4.31 ng/mL; p<0.001). These pill users also showed elevated concentrations of the inactive 5β-reductase metabolites (5β-androstanedione and 5β-androstanediol). Cycles with menstrual disturbances, such as luteal phase deficiency, also displayed altered and often lower concentrations of all urinary androgens.
conclusionThese findings highlight the significant influence of both endogenous menstrual cycle dynamics and exogenous hormone interventions on androgen availability, underscoring the necessity of considering the individual hormone status for performance optimization and athlete health management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.